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Genome-wide association (GWA) studies have identified 19 independent common risk loci for 
endometriosis. Most of the GWA variants are non-coding and the genes responsible for the association 
signals have not been identified. Herein, we aimed to assess the potential role of protein-modifying 
variants in endometriosis using exome-array genotyping in 7164 cases and 21005 controls, and a 
replication set of 1840 cases and 129016 controls of European ancestry. Results in the discovery sample 
identified significant evidence for association with coding variants in single-variant (rs1801232-CUBN) 
and gene-level (CIITA and PARP4) meta-analyses, but these did not survive replication. In the combined 
analysis, there was genome-wide significant evidence for rs13394619 (P = 2.3 × 10−9) in GREB1 at  
2p25.1 — a locus previously identified in a GWA meta-analysis of European and Japanese samples. Despite 
sufficient power, our results did not identify any protein-modifying variants (MAF > 0.01) with moderate 
or large effect sizes in endometriosis, although these variants may exist in non-European populations or 
in high-risk families. The results suggest continued discovery efforts should focus on genotyping large 
numbers of surgically-confirmed endometriosis cases and controls, and/or sequencing high-risk families to 
identify novel rare variants to provide greater insights into the molecular pathogenesis of the disease.
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Endometriosis is a common gynecological disorder, affecting 6–10% of women of reproductive age1 and 20–50% 
of women with infertility2. The disease is primarily characterized by the presence of endometrial-like tissue out-
side the uterus, mainly due to retrograde menstrual tissue/endometrial cells attaching to pelvic structures that 
trigger an inflammatory response. The most common symptoms include severe pelvic pain, heavy or irregular 
menstrual bleeding and pain during intercourse and exercise, although some women remain asymptomatic. It 
is also associated with infertility, lower abdominal and back pain, diarrhoea and/or constipation and chronic 
fatigue. Since endometriosis affects younger working age women, there are severe economic consequences arising 
from loss of income, treatment costs, depression, anxiety and other disease-related disorders, posing a significant 
burden on patients and society2. Based on location, diameter and depth of lesions, and density of adhesions, there 
are varying degrees of endometriosis severity.
According to the revised American Fertility Society (rAFS) classification system3, the disease is classified into 
one of four (I-minimal, II-mild, III-moderate and IV-severe) stages based on location, diameter and depth of 
lesions, and density of adhesions. Risk factors for endometriosis include age, increased exposure to menstruation 
(shorter cycle length, longer duration of flow, and nulliparity) and other factors related to oestrogen levels, includ-
ing decreased body mass index and smoking history4–6. The exact cause of endometriosis is largely unknown, but 
is believed to be complex, involving multiple genetic and environmental risk factors. Studies have shown that 
genes influence susceptibility to endometriosis and the disease has an estimated total heritability of around 0.51 
from twin studies1 and a SNP-based heritability of 0.267. We and others have conducted genome-wide association 
(GWA) studies for endometriosis using data from European and Japanese individuals and identified 11 independ-
ent single nucleotide polymorphism (SNP) loci at genome-wide significant level8–12. Subsequent meta-analysis 
of the European and Japanese GWA datasets further confirmed association of another locus near interleukin 1 
alpha (IL1A) at 2q13 with endometriosis13. Except for rs10965235 in CDKN2B Antisense RNA 1 (CDKN2A-AS1) 
on 9p21.3, identified in the Japanese GWA study12, the remaining 11 SNPs are polymorphic in Europeans. We 
recently performed a large-scale 1000 Genomes imputation-based GWA meta-analysis including 17045 endome-
triosis cases and 191596 controls of both European and Japanese ancestries14. In addition to replicating nine out 
of the 11 European SNP risk loci, our results identified further ten independent SNPs. Together, the 19 endome-
triosis SNPs explain up to 5.19% of variance in endometriosis14, suggesting that many more variants remain to 
be identified.
GWA studies have limitations for translation and in the genome coverage of low frequency and rare variants. 
Most common variants associated with endometriosis risk identified from GWA studies lie in non-coding regions 
of the genome and detailed follow-up studies are necessary to link causal variants to altered regulation and/or 
function of specific genes15. Imputation methods have greatly improved genome coverage for common variants, 
but the accuracy of single variant tagging by imputation declines markedly for SNPs with minor allele frequencies 
(MAFs) less than 0.0516.
An important class of variant not well covered in our GWA studies is coding variants that modify protein com-
position through amino acid substitutions or altered stop signals or splicing, particularly those with MAF < 0.05. 
Discovery of a role for this class of variants in endometriosis would be important for future translation. Coding 
variants can be evaluated by whole genome or exome sequencing methods, but the cost of these methods limits 
large-scale studies16. Here, we present results from the first exome-array analysis for endometriosis, including 
7164 cases and 21005 controls of European ancestry. Our specific aims were to identify novel coding variants 
that have not been previously captured by GWA studies as well as to assess potential role of coding variants at the 
previously known GWA risk loci.
Materials and Methods
Discovery cohorts. Six individual cohorts namely QIMR-Australia, LEUVEN-Belgium, NHS2-USA, 
BioVU-USA, WGHS-USA and iPSYCH-Denmark, participated in this effort representing a total sample size 
of 7164 endometriosis cases and 21005 controls. Full study characteristics are provided in the Supplementary 
Data. All endometriosis cases and approximately 70% controls in the QIMR-Australia cohort used in this study 
were also part of the Australian samples in our previous GWA studies9, 10. Of these, NHS2-USA contributed 
only endometriosis cases and hence were ancestrally-matched to controls from BioVU-USA, resulting in five 
individual exome-array case-control datasets (QIMR, LEUVEN, NHS2-BioVU, WGHS and iPSYCH) for fur-
ther analysis. All studies were approved by their local institutional review boards [the QIMR Human Research 
Ethics Committee (QIMR), the Commission of Medical Ethics of the Leuven University Hospital (LEUVEN), the 
Human Subject Committee of Harvard School of Public Health and the Institutional Review Board of Brigham 
and Women’s Hospital (NHS2 and WGHS), the institutional review board of Vanderbilt University, and the 
Danish Research Ethical Committee System (iPSYCH)], and written informed consent was obtained from all 
study participants. All experiments were performed in accordance to the tenets of the declaration of Helsinki (7th 
revision).
Exome-arrays. The Illumina HumanExome, HumanCoreExome and PsychArray Beadchips are genotyping 
arrays containing up to 244594 exome variants, which predominantly include protein-altering variants (nonsyn-
onymous coding, splice-site and stop gain or loss codons). Additional variants on the chip included common 
variants found through GWA studies, ancestry informative markers (for African and Native Americans), mito-
chondrial variants, randomly selected synonymous variants, HLA tag variants and Y chromosome variants. Here, 
we investigated association of autosomal and X-linked exome variants with endometriosis.
Genotyping and quality control (QC). Endometriosis cases and controls from QIMR and LEUVEN, and 
cases from NHS2 cohorts were genotyped at QIMR Berghofer Medical Research Institute, Brisbane, Australia. 
Genotyping of QIMR and NHS2 samples was performed on Illumina HumanCoreExome-12 v1.0 (~240000 
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exome variants) while LEUVEN samples were genotyped using Illumina HumanCoreExome-12 v1.1 (~244000 
exome variants). Controls from BioVU, and cases and controls from WGHS were genotyped using Illumina 
HumanExome-12 v1.1 (~243000 exome variants). Cases and controls from iPSYCH samples were genotyped on 
Illumina Infinium PsychArray-24 v1.1 (~277000 exome variants) at the Broad Institute, USA. Genotypes were 
called using the GenTrain2.0 clustering algorithm within Illumina GenomeStudio software v2011.1. All studies 
created cluster files using their own cohort data with GenomeStudio. Genotype data were then further processed 
by zCall17, a rare variant caller to attempt to re-call missing genotypes. For iPSYCH, genotypes were called at the 
Broad Institute using three different algorithms: GenCall (using a predefined cluster file), Birdseed and zCall. For 
common SNPs (MAF > 0.01) a consensus merge between GenCall and Birdseed genotypes was done. For rare 
SNPs in the consensus call (MAF < 0.01), zCall genotypes passing QCs were used.
Stringent QC criteria were applied to individual exome-array case-control dataset. Briefly, samples with > 
1% missingness, outlying heterozygosity, non-European ancestries based on the 1000 Genomes European pop-
ulations, cryptic relatedness (pi-hat > 0.2 or GCTA relatedness cut-off > 0.08) and with gender discordance 
were excluded. Similarly, markers with poor separation of three genotype clusters (cluster separation score < 0.4), 
GenTrain score < 0.6, excess heterozygosity, outlying mean beta and intensity values for heterozygote genotypes, 
> 1% missing rates and with Hardy-Weinberg Equilibrium (HWE) P < 10−6 in controls were also excluded. 
Furthermore, variants with allele frequency significantly deviated (+/− 0.2) from those in the 1000 Genomes 
European population were excluded (Supplementary Figure S1).
Single-variant association analysis. For exome variants passing the above QC, we also required minor 
allele count (MAC) > 3 in cases and controls separately before performing single-variant association analysis. 
We found this additional filter resulted in a more stable distribution of standard errors and a well-calibrated 
quantile-quantile (Q-Q) plots (Supplementary Figures S2–S6). Tests of association in individual datasets includ-
ing all endometriosis cases and controls were performed using RareMetalWorker assuming an additive model. 
RareMetalWorker is a forerunner of RareMetal18, which produces single-variant summary statistics by fitting a 
linear mixed model. Genotype data for each variant were fitted as a fixed genetic effect and a genetic relationship 
(or kinship) matrix generated from an independent set of autosomal variants with MAF > 0.01 was included 
as a random effect. Samples from iPSYCH were processed in multiple batches (‘waves’) and hence a covariate 
was also included in the model to account for potential batch effects. In addition to the score statistics for each 
marker, RareMetalWorker also generates linkage disequilibrium (LD) matrices summarizing covariance between 
single marker statistics, which can further be utilized to perform gene-level meta-analysis without requiring 
individual-level genotype data. For QIMR and iPSYCH studies, which included both male and female controls, 
X-linked markers were analysed using female controls only.
Single-variant meta-analysis. Since RareMetalWorker is designed for analysis of quantitative traits, we 
then transformed beta estimates obtained from RareMetalWorker in each dataset to a binary scale, using the 
intercept value from the null model19. For iPSYCH dataset, we used the mean trait value (i.e. the proportion of 
cases) as the analysis included a covariate in the linear mixed model. We then combined single-variant association 
results from the five case-control datasets and performed meta-analysis of all endometriosis cases versus controls, 
using a fixed-effect (inverse-variance weighted) model implemented in METAL20. Using a Bonferroni correction 
we declared a single variant as exome-wide significant if it reached P < 0.05/number of all variants reported in at 
least two individual case-control datasets. The variants with P < 1 × 10−4 were considered to show a suggestive 
association and hence were prioritized for further scrutiny.
Given the substantially greater genetic loading of moderate-to-severe (Grade B) endometriosis (rAFS III or 
IV disease) compared to mild or minimal (Grade A) endometriosis (rAFS I or II)7, 10, 21, a secondary analysis 
focused on suggestive variants (associated at P < 1 × 10−4), for which we performed meta-analysis of the associa-
tion results from QIMR and LEUVEN Grade B cases versus controls with the NHS2-BioVU, WGHS and iPSYCH 
association results. As previously shown, the exclusion of minimal endometriosis cases has the potential to enrich 
true genetic risk effects, even taking into account the reduced sample size7, 9, 10, 13, 21.
Heterogeneity of allelic associations was examined using Cochran’s Q test. Between-study (effect) hetero-
geneity was indicated by Q statistic P values (Phet) < 0.122. Meta-analysis of variants associated in fixed-effect 
model with evidence of heterogeneity (Phet < 0.1) was carried out using the Han Eskin random-effects model 
(RE2) implemented in the METASOFT program23. In contrast to the conventional random-effects model, the 
RE2 model has greater power given heterogeneity.
Conditional analysis was performed to identify additional independent association signals at loci reaching 
exome-wide significance, using single-variant association summary statistics and LD matrices from individual 
case-control datasets using RareMetal. We then performed fixed-effect meta-analysis of the association summary 
statistics across the studies using the sample size Z-score weighted method in METAL. Under this method, the 
conditional P values observed in each case-control dataset were converted into a signed Z-score. We then com-
bined Z-scores for each allele across samples in a weighted sum, with weights proportional to the square root of 
the sample size for each cohort. Given that our cohorts had unequal number of cases and controls, we used the 
effective sample size20, where Neffective = 4/(1/Ncases + 1/Ncontrols).
Gene-level meta-analysis. Using single-variant summary statistics and LD matrices for individual 
case-control datasets, gene-level meta-analysis was performed using RareMetal. In contrast to the single-variant 
meta-analysis, no MAC filter was imposed and hence all polymorphic variants within a study were considered. 
The single-variant summary statistics from all studies were then combined using the Cochran-Mantel-Haeszel 
method and computed variance-covariance matrices centrally24. We also required variants present in at least two 
individual studies and occur with a combined MAF < 0.05. We adapted an approach by Purcell et al.25 and focused 
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our analyses to three primary variant sets: (i) protein truncating variants (‘Disruptive’; nonsense, frameshift and 
essential splice-site variants), (ii) Disruptive and non-synonymous (NS) missense variants rated as “damaging” by 
all of five prediction algorithms employed (PolyPhen2-HumDiv, PolyPhen2-HumVar, LRT, MutationTaster and 
SIFT) (‘Disruptive + NSstrict’), and (iii) Disruptive, NS missense variants rated as “damaging” by all of five predic-
tion algorithms employed, and NS missense variants with a combined MAF < 0.01 rated as “damaging” by at least 
one of five prediction algorithms employed (‘Disruptive + NSstrict + NSbroad(MAF < 0.01)’). Variants were annotated 
using RefSeq and the annotation file from the CHARGE consortium (http://www.chargeconsortium.com/main/
exomechip). We used the Combined Multivariate and Collapsing (CMC) burden test26 that assumes variants are 
unidirectional in effects, and SKAT test27 that is most powerful if variants have opposite directions in effect sizes.
Replication cohort. An independent set of Icelandic endometriosis cases and controls of European origin 
from deCODE Genetics were used as our replication cohort28. Imputation of this cohort was based on whole 
genome sequencing of 8453 Icelanders using Illumina technology to a mean depth of at least 10X (median 32X). 
Approximately 30 million sequenced variants were then imputed into 150656 Icelanders who had been geno-
typed using Illumina genotyping arrays. Using genealogic information, the sequence variants were imputed into 
294212 un-typed relatives of chip-typed individuals to further increase the sample size for association analysis 
and increased the power to detect associations. Of these, our replication cohort included 1840 surgically diag-
nosed endometriosis cases and 129016 controls, with 688 cases exhibiting moderate-to-severe (rAFS III or IV) 
disease. We excluded poorly imputed variants with imputation quality metric < 0.8.
Replication and total association analyses. Association analysis of the imputed data in the deCODE 
replication cohort was performed as previously described28, and variants with a nominal P < 0.05 were consid-
ered to have replicated. To determine the total evidence for association, we combined single-variant association 
results from five individual case-control datasets with those from the deCODE, and performed a fixed-effect 
(inverse-variance weighted) meta-analysis for all endometriosis cases versus controls. Additional meta-analysis 
for QIMR and LEUVEN Grade B cases versus controls, NHS2-BioVU, WGHS and iPSYCH all cases versus con-
trols and the deCODE Grade B cases versus controls was also performed for the variants showing suggestive 
association at P < 1 × 10−4 in exome-array single-variant meta-analysis of all cases versus controls.
Results
Following quality control (QC), a total of 7164 endometriosis cases and 21005 controls from five individual 
case-control datasets in the discovery sample remained for the primary exome-array meta-analysis (Table 1). 
The number of variants passing the QC in each case-control dataset is provided in Supplementary Table S1. A 
total of 162203 variants passed the QC in at least two studies and were included in the gene-level analysis, and of 
these, 126317 were rare (MAF < 0.01), 8859 had low frequency (0.01 ≤ MAF < 0.05) and 27027 were common 
(MAF ≥ 0.05) in the combined discovery datasets. We restricted our single-variant analysis to 59202 variants with 
minor allele count (MAC) > 3 in cases and controls separately in each exome-array dataset and also present in at 
least two studies. Of these, 23755 were rare, 8858 had low frequency, and the remaining 26589 were common in 
the combined discovery datasets. Consequently, the exome-wide significance threshold for single-variant analy-
ses was set at P < 8.5 × 10−7, corresponding to Bonferroni correction for the 59202 variants. The Q-Q plot for P 
values obtained from single-variant meta-analysis is shown in Supplementary Figure S7.
Exome variants associated with endometriosis risk. Single-variant meta-analysis for the five indi-
vidual case-control datasets identified a non-synonymous coding variant (rs1801232) associated with endo-
metriosis risk reaching exome-wide significance. The effect allele (T) occurring with a combined effect allele 
frequency (EAF) of 0.08 was associated with a decreased risk [odds ratio (OR) = 0.82; 95% confidence inter-
val (CI) = 0.76–0.89] (Table 2 and Fig. 1). The direction of effect of the T allele was consistent across studies, 
except in the iPSYCH, with no statistically significant heterogeneity observed among all studies (Phet = 0.25) in 
allelic associations. Similar results (OR = 0.82; 95% CI = 0.75–0.89; P = 2.0 × 10−6; Phet = 0.36), although not 
exome-wide significant, were also observed when the meta-analysis was performed after excluding Grade A cases 
(Supplementary Table S2). Conditional analysis including all endometriosis cases and controls in the discov-
ery sample did not identify further independent association signals at this locus. SNP rs1801232 is a missense 
variant (p.Asn3552.Lys) located in the Cubilin (CUBN) gene at chromosome 10p13 - a locus associated with 
Dataset
Number of cases 
(Grade B)
Number of 
controls
QIMR 2223 (891) 2044
LEUVEN 998 (423) 783
NHS2-BioVU 2238 3113
WGHS 1494 14033
iPSYCH 211 1032
Exome-array meta-analysis 7164 21005
deCODE Replication 1840 (688) 129016
Total 9004 150021
Table 1. Summary of the endometriosis case-control datasets (post-QC).
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albuminuria29, 30. The protein encoded by CUBN plays a role in lipoprotein, vitamin and iron metabolism, by 
facilitating their uptake.
Our primary exome-array meta-analysis including all cases also identified a further 21 variants showing sug-
gestive (P < 1 × 10−4) association with endometriosis risk (Table 2). Most (n = 12) in the list are coding variants, 
with 11 non-synonymous and one synonymous variant, and of these five are low frequency coding variants. 
Interestingly, two (rs6542095 and rs13394619) out the nine non-coding SNPs in the list, are located in genes previ-
ously associated GWA risk loci, both reported by ourselves9, 13. The intergenic SNP rs6542095 near IL1A is ranked 
second in the list of 22 variants, and the effect allele T is strongly associated with decreased risk (OR = 0.89; 
95% CI = 0.85–0.94; P = 1.7 × 10−6; Phet = 0.75) of endometriosis (Table 2), with slightly stronger associa-
tion (OR = 0.88; 95% CI = 0.84–0.93; P = 8.9 × 10−7; Phet = 0.56) with Grade B endometriosis (Supplementary 
Table S2). SNP rs13394619 is intronic to the growth regulation by estrogen in breast cancer 1 gene (GREB1) where 
it disrupts a splice site, and the effect allele A is also associated with decreased risk (OR = 0.92; 95% CI = 0.88–
0.96; P = 5.8 × 10−5; Phet = 0.61) of endometriosis (Table 2), with similar results (OR = 0.92; 95% CI = 0.88–0.96; 
P = 4.6 × 10−4; Phet = 0.69) in Grade B analysis (Supplementary Table S2). Association results of all the 22 variants 
in the individual exome-array dataset are provided in Supplementary Table S3.
In our replication analysis, rs1801232 with exome-wide significance did not replicate (P = 0.37) in an inde-
pendent set of endometriosis cases and controls from the deCODE Genetics cohort. Results including Grade B 
cases in the deCODE cohort (OR = 0.99; P = 0.95) were also not significant. Consequently, rs1801232 did not 
retain exome-wide significance in the total association analyses (‘All’: P = 4.2 × 10−6, ‘Grade_B’: P = 1.6 × 10−5) 
after combining results from both discovery and replication cohorts (Table 2 and Supplementary Table S2). 
The association strength did not increase (P = 5.9 × 10−6) even after accounting for the observed heterogeneity 
through an all endometriosis total association analysis (Phet = 0.09) in the RE2 model.
Of the remaining 21 variants with P < 1 × 10−4 in the exome-array single-variant meta-analysis including 
all endometriosis cases and controls, two intergenic common SNPs (rs13394619 and rs9354308) survived inde-
pendent replication (P < 0.05) in the deCODE cohort including all endometriosis cases, with the same direction 
of effect to those observed in the discovery cohorts (Table 2 and Supplementary Table S3). SNP rs13394619 is the 
GREB1 GWA signal that showed associations with both all (P = 7.4 × 10−7) (Table 2) and Grade B (P = 0.032) 
(Supplementary Table S2) endometriosis. The other intergenic SNP rs9354308 near solute carrier family 25 mem-
ber 51 pseudogene 1 (SLC25A51P1) also survived independent replication in analysis including all (P = 0.03) but 
not Grade B (P = 0.42) endometriosis cases from deCODE cohort.
In the total association analysis including results from both the discovery and replication cohorts, the GREB1 
GWA signal achieved genome-wide significance (OR = 0.89; 95% CI = 0.86–0.93; P = 2.3 × 10−9; Phet = 0.17) with 
Chr dbSNP ID
Position 
(bp)
Functional 
region Genes EA NEA
Exome-array meta-analysis (all) deCODE replication (all) Total association analysis (all)
EAF OR (95% CI) P Phet PRE2 OR (95% CI) P OR (95% CI) P Phet PRE2
10 rs1801232 16870912 NS CUBN T G 0.08 0.82 (0.76–0.89) 7.47 × 10–7 0.25 0.95 (0.84–1.07) 0.37 0.86 (0.80–0.92) 4.18 × 10−6 0.09 5.97 × 10–6
2 rs6542095 113529183 intergenic IL1A T C 0.69 0.89 (0.85–0.94) 1.71 × 10–6 0.75 0.93 (0.86–1.01) 0.07 0.90 (0.87–0.94) 4.39 × 10−7 0.76
7 rs17172694 46437154 intergenic IGFBP3 T G 0.08 1.21 (1.11–1.30) 3.27 × 10−6 0.52 1.11 (0.99–1.25) 0.09 1.18 (1.10–1.26) 1.33 × 10−6 0.48
16 rs78108426 11001421 NS CIITA A C 0.01 1.87 (1.40–2.49) 1.90 × 10−5 0.07 2.40 × 10−5 0.34 (0.11–1.05) 0.06 1.68 (1.28–2.22) 2.31 × 10−4 0.004 6.99 × 10−5
10 rs138680811 98157006 NS TLL2 A G 0.003 2.44 (1.61–3.71) 2.72 × 10−5 0.40 1.96 (0.88–4.40) 0.10 2.33 (1.61–3.38) 7.49 × 10−6 0.53
2 rs17261772 135911422 synonymous RAB3GAP1 T C 0.74 0.88 (0.83–0.94) 3.33 × 10−5 0.0007 1.27 × 10−6 1.02 (0.91–1.14) 0.78 0.91 (0.86–0.96) 4.20 × 10−4 0.0002 3.87 × 10−6
10 rs12777823 96405502 intergenic CYP2C18 A G 0.15 1.13 (1.07–1.20) 3.39 × 10−5 0.15 0.99 (0.89–1.11) 0.88 1.10 (1.05–1.16) 3.08 × 10−4 0.05 1.58 × 10−4
4 rs4647930 1018705 NS FGFRL1 A C 0.27 0.90 (0.86–0.95) 3.98 × 10−5 0.10 1.04 (0.96–1.13) 0.31 0.94 (0.90–0.98) 2.83 × 10−3 0.004 3.27 × 10−4
16 rs1639150 3747204 intronic TRAP1 T C 0.43 0.91 (0.88–0.95) 4.25 × 10−5 0.92 1.04 (0.97–1.12) 0.32 0.94 (0.91–0.98) 2.54 × 10−3 0.09 1.61 × 10−3
17 rs2278868 46262171 NS SKAP1 T C 0.61 1.10 (1.05–1.14) 4.38 × 10−5 0.35 1.07 (1.00–1.16) 0.07 1.09 (1.05–1.13) 8.73 × 10−6 0.45
2 rs114242502 235951001 NS SH3BP4 A G 0.00 5.62 (2.45–12.89) 4.53 × 10−5 0.002 5.61 × 10−6 2.76 (0.07–115.4) 0.59 5.44 (2.42–12.22) 4.18 × 10−5 0.01 6.49 × 10−6
3 rs3772836 124535635 intronic ITGB5 A C 0.04 0.80 (0.72–0.89) 4.70 × 10−5 0.29 1.13 (0.96–1.34) 0.15 0.89 (0.81–0.97) 9.11 × 10−3 0.005 5.21 × 10−4
2 rs13394619 11727507 splicing GREB1 A G 0.48 0.92 (0.88–0.96) 5.77 × 10−5 0.61 0.83 (0.77–0.90) 7.43 × 10−7 0.89 (0.86–0.93) 2.33 × 10−9 0.17
9 rs512110 79320640 NS PRUNE2 T C 0.76 1.11 (1.05–1.16) 6.61 × 10−5 0.71 1.04 (0.95–1.13) 0.38 1.09 (1.04–1.14) 1.04 × 10−4 0.59
12 rs12313736 26383959 NS SSPN A G 0.04 1.25 (1.12–1.39) 6.73 × 10−5 0.70 1.05 (0.86–1.30) 0.63 1.20 (1.09–1.32) 1.67 × 10−4 0.53
6 rs9354308 66565353 intergenic SLC25A51P1 A G 0.63 0.91 (0.87–0.96) 6.88 × 10−5 0.94 0.92 (0.86–0.99) 0.03 0.92 (0.88–0.95) 6.69 × 10−6 0.98
10 rs12767583 96547463 intronic CYP2C19 T C 0.15 1.13 (1.06–1.20) 7.07 × 10−5 0.54 0.98 (0.88–1.10) 0.77 1.10 (1.04–1.15) 6.97 × 10−4 0.19
4 rs11131511 64933220 intergenic LPHN3-AS1 T G 0.54 1.09 (1.05–1.14) 7.24 × 10−5 0.30 0.95 (0.89–1.03) 0.21 1.05 (1.02–1.09) 6.08 × 10−3 0.01 1.08 × 10−3
2 rs1446585 136407479 intronic R3HDM1 A G 0.70 0.89 (0.84–0.94) 8.08 × 10−5 0.001 4.63 × 10−6 0.98 (0.89–1.09) 0.73 0.91 (0.87–0.96) 3.04 × 10−4 0.001 1.13 × 10−5
12 rs12313670 26383834 NS SSPN A G 0.04 1.24 (1.12–1.38) 8.42 × 10−5 0.75 1.05 (0.85–1.30) 0.63 1.20 (1.09–1.32) 1.96 × 10−4 0.59
10 rs1126545 96493058 NS CYP2C18 T C 0.15 1.13 (1.06–1.19) 8.51 × 10−5 0.60 0.98 (0.88–1.10) 0.76 1.09 (1.04–1.15) 8.53 × 10−4 0.21
22 rs148613283 18301508 NS MICAL3 T C 0.99 1.68 (1.29–2.17) 9.04 × 10−5 0.40 1.17 (0.68–2.01) 0.58 1.57 (1.24–1.98) 1.61 × 10−4 0.37
Table 2. Summary of the exome-array meta-analysis and replication results for markers with P < 1 × 10–4 in 
analysis including ‘All’ endometriosis cases. Chr, Chromosome; Genomic position is shown relative to GRCh37 
(hg19); NS, nonsynonymous; EA, effect allele; NEA, non-effect allele; EAF, average effect allele frequency in the 
discovery cohorts; OR, odds ratio with respect to EA; CI, confidence interval; Phet, P-value from heterogeneity 
test; PRE2, P-value from the Han Eskin random-effects (RE2) model.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 11380  | DOI:10.1038/s41598-017-10440-9
all endometriosis cases (Table 2 and Fig. 2). The association signal persisted (P = 5.3 × 10−5; Phet = 0.73), albeit not 
genome-wide significant, in analysis including Grade B cases (Supplementary Table S2). Similarly, the IL1A GWA 
signal showed a near genome-wide significant (P = 4.4 × 10−7; Phet = 0.76) association with all (Table 2) endome-
triosis and the signal was comparable for Grade B (P = 5.1 × 10−7; Phet = 0.65) cases (Supplementary Table S2), 
with no evidence of heterogeneity in allelic associations (Phet = 0.55).
Genes associated with endometriosis risk. We also carried out gene-level meta-analysis using burden 
and SKAT tests for the three alternate variant sets, as described in Methods. Gene-based tests take into account over-
all variant-load within a specific gene/locus and therefore may have greater power than single-variant tests to detect 
multiple rare and low frequency alleles. We tested a total of 755, 3635 and 12373 genes with at least two variants in 
‘Disruptive’, ‘Disruptive + NSstrict’ and ‘Disruptive + NSstrict + NSbroad(MAF < 0.01)’ categories, respectively. We declared a 
gene-based association as exome-wide significant at P < 1.5 × 10−6, corresponding to Bonferroni correction for the 
16763 genes each for burden and SKAT tests. For gene-based tests reaching exome-wide significance, if the signal was 
driven by a single variant, we also required the variant to achieve exome-wide significance in the single-variant test.
Results from gene-based meta-analysis identified class II major histocompatibility complex transactivator 
(CIITA) and poly(ADP-ribose) polymerase family member 4 (PARP4) as associated with endometriosis risk at 
exome-wide significance level (Supplementary Table S5). CIITA showed exome-wide significant association in 
both burden (P = 5.9 × 10−7) and SKAT (P < 1.5 × 10−9) tests (Supplementary Tables S4 and S5), and the gene 
included eight non-synonymous coding variants with an average combined MAF of 0.0008. The observed CITTA 
genic signal included eight variants and the association was primarily driven by three variants (rs144646271, 
rs78108426 and rs113889330) with single-variant meta-analysis P values as 0.003, 9.1 × 10−6, 0.08, respec-
tively (Supplementary Tables S4 and S5). We could not examine the genic association of CIITA in our inde-
pendent deCODE cohort because directly measured genotype data were not available. However, results from 
single-variant analyses including both all and Grade B cases in deCODE indicated borderline association for 
rs78108426 (P < 0.06 and 0.05, respectively), but the direction of effect was opposite to the discovery cohorts. SNP 
rs144646271 showed P values of 0.28 and 0.50 in all and Grade B cases, respectively, and data for rs113889330 was 
not available in the deCODE cohort.
PARP4 also showed exome-wide significant association with endometriosis risk in the SKAT test (P = 5.9 × 10−7). 
The PARP4 genic signal was also strong in the burden test (P = 1.4 × 10−5) (Supplementary Table S4). While 
PARP4 included two splicing variants (rs201251739 and rs142749081) with an average combined MAF of 0.0002, 
the observed genic association signal in SKAT test was primarily driven by rs201251739 with a single-variant 
meta-analysis P = 3.2 × 10−7. However, considering 158914 polymorphic autosomal variants in at least two indi-
vidual studies used to produce gene-level meta-analysis results, rs201251739 does not reach the exome-wide signif-
icance level in the corresponding single-variant test. Notably, rs201251739 does not replicate in both all (P = 0.87) 
and Grade B (P = 0.91) deCODE cohort. As such, the genic signal for PARP4 observed in SKAT could not be con-
sidered to achieve the exome-wide significance. Other genes observed in the list of top five hits in each of the three 
variant (‘Disruptive’, ‘Disruptive + NSstrict’ and ‘Disruptive + NSstrict + NSbroad(MAF < 0.01)’) categories from both burden 
and SKAT tests (P < 1.1 × 10−3) are provided in Supplementary Tables S4 and S5, respectively).
Discussion
In this study we genotyped endometriosis cases and controls using Illumina genotyping arrays containing the 
Human Exome content with 244594 variants. The coding variants can change protein function and any such 
variants associated with endometriosis would highlight genes directly responsible for increased disease risk. The 
Figure 1. Manhattan plot of the exome-array single-variant meta-analysis results including all endometriosis 
cases. Red line indicates our exome-wide significance threshold (P = 8.5 × 10–7) and the orange line represents 
the threshold for suggestive association (P = 1 × 10–4). SNP rs1801232 (red font) on chromosome 10 achieved 
our exome-wide significance threshold. Two other SNPs rs6542095 and rs13394619 (light orange font) on 
chromosome 2 also showed strong, albeit not exome-wide significant, association in the exome-array meta-
analysis of discovery cohorts. These two SNPs represent the previously identified GWA association signals at 
IL1A and GREB1, respectively and of these rs13394619 achieved genome-wide significance in total association 
analysis including all cases from both the discovery and the replication cohorts.
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majority of variants are rare or occur with a low frequency and hence may not be well imputed in GWA studies16. 
This study, including data from 9004 endometriosis cases and 150021 controls of European ancestry, represents 
the first large discovery effort to search for association between exome variants and endometriosis and provides 
important insights on their potential impact in endometriosis pathogenesis.
Following single variant analysis of 59202 variants passing our quality control on the Illumina exome-arrays, 
there was one missense variant (rs1801232; p.Asn3552.Lys) in CUBN that reached exome-wide significance level. 
Our gene-based analyses of exome-array data identified CIITA and PARP4 as significantly associated with endo-
metriosis susceptibility. The CIITA genic signal was primarily driven by three missense variants that also showed 
significant associations in single-variant meta-analysis, lending support to the observed gene-based signal. The 
PARP4 signal was mainly driven by a single variant. However, the association with rs1801232 in CUBN and the 
CIITA and PARP4 genic signals could not be replicated in an independent dataset. Neither CIITA nor PARP4 
showed association with endometriosis in the GWA gene-based analyses14, although CUBN was nominally sig-
nificant (P = 1.35 × 10−3).
Exome-arrays provide a fast and economical platform to investigate the role of coding variants, but have 
some limitations31. Whole genome or exome sequencing would provide a more comprehensive evaluation of 
coding variants, including novel variants, copy number variants, and structural variation. However, the cost of 
exome sequencing remains high limiting use for large-scale studies with sufficient power to detect association 
with low-frequency variants. The variants included in the exome-arrays are estimated to represent 97–98% of 
the non-synonymous, and 94–95% of the splice altering and stop altering variants detected in an average genome 
through exome sequencing (http://genome.sph.umich.edu/wiki/Exome_Chip_Design#Online_Content). Our 
discovery sample size had ~93% and ~89% power to detect exome variants of frequency 0.05 and 0.01 contribut-
ing to genotype relative risk of 1.30 and 1.65, respectively32, and if low frequency coding variants with moderate 
effect size contributed to endometriosis risk they would have been observed in this study. We cannot rule out the 
possibility that low frequency coding variants with moderate or large effects exist in non-Europeans or severely 
affected families, but our results did not identify any coding variants (MAF > 0.01) with moderate or large effect 
sizes influencing endometriosis risk.
Results from previous studies have shown that moderate-to-severe endometriosis cases have greater genetic 
loading than minimal or mild disease9, 10, 21. Only about 18% of endometriosis cases in our discovery sample 
had moderate-to-severe disease and hence this study may not have adequately examined the potential impact of 
coding variants in severe cases. Moreover, 77% (gene-based analysis) and 40% (single-variant tests) of the exome 
variants examined in this study are rare (MAF < 0.01), and our study had limited power to detect association of 
such variants with endometriosis. Additionally, very rare variants (MAF < 0.001) are not well captured by this 
Figure 2. Evidence of association with all endometriosis from the total association analysis across the 2p25.1 
(GREB1) region. SNPs are shown as circles, triangles or squares, and different shapes denote the different 
categories of the SNPs: up-triangle for frameshift or splice SNPs, down-triangle for nonsynonymous SNPs, 
square for coding or untranslated region (UTR) SNPs; star for SNPs in tfbscons region (in a conserved 
region predicted to be a transcription factor binding site), square filled with ‘X’ symbol for SNPs located in 
mcs44placental region (in a region highly conserved in placental mammals) and circle for SNPs with no 
annotation information. The lead SNP at each known GWA risk locus reported by Nyholt et al.9, if present 
in our exome-array single-variant meta-analysis, is represented by a purple triangle. All other SNPs are color 
coded according to the strength of LD with the top genotyped SNP (as measured by r2 in the European 1000 
Genomes data).
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 11380  | DOI:10.1038/s41598-017-10440-9
exome-array based approach. Whole exome sequencing in reasonably large samples, possibly tens of thousands 
of cases and similar number of controls, or high-risk families will be required to fully understand the role for rare 
coding variation in endometriosis pathogenesis. However, given a fixed budget and the relative costs of genotyp-
ing arrays and whole genome sequencing, genotyping and imputation of a much larger sample will have greater 
power to detect both common and low frequency variants16. The large reference panel now available for imputa-
tion further increases the accuracy of imputation of low frequency and rare variants33.
Results from the analysis of both discovery and replication samples did provide support for near genome-wide 
significant association for rs6542095 near IL1A and significant association of the splice variant rs13394619 at 
the GREB1 locus with endometriosis. SNP rs6542095 is intergenic, located ~34 kb distant and in very strong LD 
(r2 = 0.96) with rs10167914, the most strongly associated SNP at this locus in a recent study of common variants 
associated with endometriosis14. The GREB1 signal was first identified by ourselves34 in the GWA meta-analysis 
comprising both European and Japanese individuals. In the current study of European samples, results for 
rs13394619 were genome-wide significant (P = 2.3 × 10−9), although this includes the Australian samples (all 
endometriosis cases and approximately 70% of the controls) from our previous GWA meta-analysis. The effect 
size was similar, and the direction was consistent with previous reports and exclusion of the Australian samples 
provided comparable results (OR = 0.89 and P = 5.8 × 10−8). GREB1 is an excellent candidate in endometriosis 
pathogenesis because of its known estrogen-responsive properties and previous reports of altered GREB1 expres-
sion both at mRNA and protein levels35. Recent meta-analysis of common variants associated with endometrio-
sis14 identified two independent signals at the GREB1 locus, rs77294520 located approximately 13 kb upstream 
of GREB1 and rs11674184 located in intron 7 of GREB1. The SNP rs13394619 is a splice acceptor variant located 
approximately 6 kb from rs11674184 and the two SNPs are in strong LD (r2 = 0.66) based on the 1000 Genomes 
Europeans data. The Ensembl database36 reports 10 transcripts for GREB1 producing 8 different proteins and 
effects of rs13394619 on specific GREB1 transcripts should be evaluated in RNA sequence data for endometrium.
There was no evidence that coding variants in other relevant genes can account for the association of pre-
viously identified GWA risk loci with endometriosis (Supplementary Figures S8–S14). A number of candidate 
gene studies tested association with coding variants, although many had issues with study design and very few 
results have been replicated37, 38. Our results did not identify association with coding variants in any of the candi-
date genes including genes involved in steroid hormone synthesis and response (aromatase (CYP19A1), estrogen 
receptor 1 (ESR1), estrogen receptor 2 (ESR2), or progesterone receptor (PGR)), or strong independent associa-
tion in genes within regions identified from GWA studies. The most recent GWA meta-analysis including 17045 
endometriosis cases and 191596 controls of both European and Japanese ancestries14 identified 19 independent 
signals in 14 genomic regions associated with endometriosis, which together explain 1.75% and 5.19% of variance 
in all and moderate-to-severe endometriosis14. In addition to GREB1, the meta-analysis identified risk variants 
located near genes for ESR1 and follicle stimulating hormone beta subunit (FSHB). Lack of evidence for coding 
variants associated with endometriosis in these or other genes within regions identified from GWA studies sug-
gests common causal variants associated with disease act through functional changes in regulatory sequences in 
these regions.
In summary, we conducted the first large exome-array analysis and evaluated the potential role of coding 
variants in endometriosis risk. Despite sufficient power, our results did not identify any coding variants (MAF > 
0.01) with moderate or large effect sizes in endometriosis pathogenesis, although we will have missed variants not 
assayed on the Illumina exome-arrays. Only ~23% of the exome variants examined in this study occur with MAF 
> 0.01 and our results do not exclude effects of rare variants in other populations or high risk families. Our results 
did not identify association with coding variants in most putative candidate genes, but do provide additional 
evidence for genome-wide significant evidence for association with a splice variant in the GREB1 locus in women 
with European ancestry. We conclude that continuing gene discovery efforts in endometriosis should focus on 
genotyping large numbers of surgically confirmed endometriosis cases and controls. In addition, sequencing 
high-risk families may identify novel rare variants that could provide further insights into the molecular patho-
genesis of the disease.
Data availability. The authors declare that the data supporting the findings of this study are available within 
the article and its supplementary information files. For additional data (beyond those included in the main text 
and Supplementary Information) that support the findings of this study, please contact the corresponding author.
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